A six-state cash-pay service selling compounded semaglutide and tirzepatide at one flat price per dose, billed every four weeks rather than monthly.
- Semaglutide$159/mo
- Tirzepatide$189/mo
Assume we may earn a commission, at no cost to you. Partners we work with carry a small, fixed edge in where they are listed; the scores themselves are not adjusted.
- Semaglutide
- $159/mo (billed every 4 weeks)
- Tirzepatide
- $189/mo (billed every 4 weeks)
- Coverage
- 6 states
- Brand-name
- Compounded only
The scorecard
TrueMe scored on our six published factors. See the methodology.
What we like
- Full price list is public on the homepage and both treatment pages, with no intake form or account required to see it
- The same price applies at every dose, so the bill does not climb as a provider titrates upward
- The quoted price covers the medical intake, the medication, temperature-controlled shipping, administration supplies and provider messaging, with no separate membership fee
- Names its telehealth platform (Telegra), its physician network (Strive) and a returns pharmacy (CarePoint Infusion Pharmacy, Stafford, Texas)
The caveats
- Compounded semaglutide and tirzepatide are not FDA-approved; the FDA does not review them for safety, effectiveness or quality
- Everything marketed as 'per month' is charged every four weeks at checkout, which is thirteen charges a year rather than twelve
- The advertised three-month rates of $119 and $139 are a single upfront charge of $357 or $417, not a lower monthly plan
- You pay before the health questionnaire, so the card is charged before any clinician has decided whether to prescribe
- Available in six states only, and on 1 August 2026 the homepage still listed five while the treatment pages listed six
The verdict
Best for: Someone in Arizona, Colorado, Missouri, Pennsylvania, Texas or Wisconsin who wants the full price visible before answering a single health question.
Ranked #367 of 548 providers we have reviewed — for comparison, read the CoreAge Rx review, ranked #1. In the ranking it sits between Woodwork at #366, 61/100 above and Cielo at #368, 60/100 below, with the Rehydra+ Wellness write-up the next one down.
Weighing it against something else? Every provider we would put in front of TrueMe is ranked on price honesty, prescriber access and cancellation terms. If you would rather start from the top of the field, our full board of 548 providers is the place to start if you are still shortlisting. We have also compared it head to head: CoreAge Rx vs TrueMe goes to CoreAge Rx, 94/100 to 60/100.
Compare TrueMe
Compare with other providers
The closest reviews to TrueMe by Verdict Score — the realistic shortlist if you are weighing this one up.
- #344Silhouette MD— Concierge-style GLP-1 telehealth offering compounded semaglutide and tirzepatide in both injectable and oral forms, with provider oversight and full-service support included on every plan.62/100
- #345TeleHealth Med— TeleHealth Med (TeleHealth Med, Inc.) is a Georgia-based telehealth weight-loss platform offering compounded semaglutide and tirzepatide in both injectable and sublingual forms through US-licensed…62/100
- #346Spry— Spry is a weight-loss and anti-aging telehealth platform pairing compounded semaglutide ($199/mo) and tirzepatide ($299/mo) with three longevity peptides — BPC-157, NAD+, and sermorelin ($249–$299/mo).62/100
- #347Luvo Health— Publishes an unusually complete price grid covering compounded injections, oral tablets and brand Ozempic and Zepbound, but charges you before any clinician has reviewed your intake.59/100
- #348VevaRX— Publishes a real 36-state list, then prices tirzepatide only by the quarter and carries another company's copy inside its own legal pages.61/100
- #349BeyondMD— Telehealth clinic offering competitively priced compounded semaglutide and tirzepatide.61/100
Pricing, states and verification reflect TrueMe's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on TrueMe's site. Not medical advice; see our disclosure.